Pediatric Antipsychotic Medication Use in Children | NSCP PD Credits: 2

Sale!
Pediatric medication

The use of antipsychotic medications in children has increased significantly in school-aged populations. School psychologists play a critical role in understanding how these medications impact learning, behavior, and mental health in educational settings.

Original price was: $20.00.Current price is: $16.00.

Pediatric Antipsychotic Medication Use in Children

NCSP-Approved Professional Development | 2 CPD Credits This course includes essential information on Pediatric Antipsychotic Medication.

The use of antipsychotic medications in children has increased significantly in school-aged populations. School psychologists play a critical role in understanding how these medications impact learning, behavior, and mental health in educational settings. This 2-credit professional development course equips school psychologists with essential knowledge to support students receiving pediatric antipsychotic medications.

This course provides a clear overview of commonly prescribed antipsychotic medications, their intended uses, and potential side effects that may affect academic performance, behavior, and social-emotional functioning. Participants learn how medication use intersects with school-based services, behavioral interventions, and progress monitoring.

Designed specifically for school psychologists, this training emphasizes ethical practice, collaboration, and data-based decision-making. Participants gain practical guidance on how to monitor student functioning, communicate concerns appropriately, and collaborate with families, educators, and medical providers while staying within professional scope of practice.

By the end of the course, participants will feel confident interpreting the school-based implications of antipsychotic medication use and supporting students through informed consultation and evidence-based recommendations.

Learning Objectives

By the end of this course, school psychologists will be able to:

  • Identify common antipsychotic medications prescribed to children and their primary indications

  • Recognize potential side effects that may impact behavior, attention, learning, and health in school settings

  • Use data-based observation and monitoring to support students receiving antipsychotic medications

  • Collaborate ethically with families, educators, and medical professionals within scope of practice

  • Integrate medication considerations into comprehensive intervention planning

NCSP Credit Alignment & Domains of Practice

This course qualifies for NASP-approved continuing professional development (CPD) hours and may be applied toward the 75 CPD hours required for NCSP renewal.

The content aligns with the following NCSP Domains of Practice:

  • Domain 1: Data-Based Decision Making
    Monitoring student response to medication and behavioral interventions using data.

  • Domain 2: Consultation and Collaboration
    Partnering with families, educators, and healthcare providers to support student needs.

  • Domain 4: Interventions and Mental Health Services
    Understanding how medication interacts with behavioral and mental health supports.

  • Domain 8: Legal, Ethical, and Professional Practice
    Applying ethical guidelines, professional boundaries, and informed decision-making.

Course Details

  • Audience: School Psychologists

  • Format: Online, self-paced

  • Length: 2 CPD Credits

  • Approval: NASP-approved for NCSP renewal

  • Focus: Pediatric antipsychotic medication use in educational settings

Delivery

Asynchronous video course
PD Clock Hours

2 Hours

Accreditation

NASP Approved Provider #1152

 

 

Author

Polina Kalmanovich, PharmD, MS, is a highly accomplished biopharmaceutical executive with over 15 years of leadership experience in global regulatory affairs, program management, and business strategy across neurology, psychiatry, infectious disease, urology, and pain therapeutics.

Dr. Kalmanovich currently serves as Executive Director and Head of Program Management and Business Analytics at Sarepta Therapeutics, where she leads teams responsible for strategic portfolio planning, operational excellence, and cross-functional collaboration across global R&D programs. Her prior roles at Sarepta include Executive Director of Business Strategy and Operations and Senior Director of Global Regulatory Affairs, where she spearheaded key initiatives in gene therapy research and regulatory strategy for early- and late-stage development programs.

Before joining Sarepta, Dr. Kalmanovich held senior positions at Novus Therapeutics and Allergan, Inc., leading global registration efforts and regulatory negotiations with the FDA, EMA, and PMDA. She also contributed to neuroscience drug development through her work at Chase Pharmaceuticals and served in the FDA Office of Policy early in her career.

A Doctor of Pharmacy and Master of Science in Regulatory Science graduate from the University of Southern California, Dr. Kalmanovich also completed the General Management Program at Harvard Business School. She is a licensed pharmacist in California and a published researcher in neurobiology, fluent in both English and Russian.

Dr. Kalmanovich brings a wealth of expertise in clinical development, regulatory innovation, and leadership — along with a passion for mentoring future professionals in science, healthcare, and applied behavior analysis.

Scroll to Top